Dara Azar
Stock Analyst at Stifel Nicolaus
(1.29)
# 3,720
Out of 5,090 analysts
24
Total ratings
30.8%
Success rate
-2.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dara Azar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INBX Inhibrx Biosciences | Reiterated: Buy | $325 | $71.78 | +352.77% | 9 | Oct 29, 2026 | |
| IMNM Immunome | Reiterated: Hold | $24 | $18.21 | +31.80% | 2 | Oct 6, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $3.24 | +177.78% | 1 | Oct 1, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Buy | n/a | $16.03 | - | 8 | Sep 29, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $82 | $44.25 | +85.31% | 4 | Aug 13, 2026 |
Inhibrx Biosciences
Oct 29, 2026
Reiterated: Buy
Price Target: $325
Current: $71.78
Upside: +352.77%
Immunome
Oct 6, 2026
Reiterated: Hold
Price Target: $24
Current: $18.21
Upside: +31.80%
Whitehawk Therapeutics
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.24
Upside: +177.78%
Summit Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $16.03
Upside: -
Enliven Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $82
Current: $44.25
Upside: +85.31%